Immunovant, Inc.
IMVT
$31.48
-$0.13-0.41%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -14.41% | -21.96% | -5.19% | 38.37% | 36.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.17% | 0.05% | 13.84% | 34.94% | 40.73% |
| Operating Income | -40.17% | -0.05% | -13.84% | -34.94% | -40.73% |
| Income Before Tax | -42.35% | 1.70% | -15.47% | -37.47% | -40.99% |
| Income Tax Expenses | -587.82% | 921.05% | 661.54% | 1,085.71% | 151.29% |
| Earnings from Continuing Operations | -38.90% | 0.44% | -15.93% | -38.40% | -41.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.90% | 0.44% | -15.93% | -38.40% | -41.33% |
| EBIT | -40.17% | -0.05% | -13.84% | -34.94% | -40.73% |
| EBITDA | -40.22% | -0.05% | -13.84% | -34.94% | -40.71% |
| EPS Basic | -13.69% | 19.41% | 2.21% | -18.32% | -23.20% |
| Normalized Basic EPS | -16.53% | 20.44% | 2.60% | -17.53% | -22.89% |
| EPS Diluted | -13.69% | 19.41% | 2.21% | -18.32% | -23.20% |
| Normalized Diluted EPS | -16.53% | 20.44% | 2.60% | -17.53% | -22.89% |
| Average Basic Shares Outstanding | 22.18% | 23.54% | 18.55% | 16.97% | 14.71% |
| Average Diluted Shares Outstanding | 22.18% | 23.54% | 18.55% | 16.97% | 14.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |